Podcast Beta
Questions and Answers
Phenoxybenzamine has a plasma half-life of approximately how many hours?
Which route of administration is NOT suitable for all α-blockers except phentolamine?
Phenoxybenzamine binds covalently to which receptors?
In addition to pheochromocytoma, phenoxybenzamine can also be used to control episodes of which symptoms?
Signup and view all the answers
Which route of administration is phenoxybenzamine active by?
Signup and view all the answers
What is the duration of action of phenoxybenzamine after a single dose?
Signup and view all the answers
What effect does phenoxybenzamine have on parasympathetic nerves?
Signup and view all the answers
Besides pheochromocytoma, what else can phenoxybenzamine be used to control?
Signup and view all the answers
Study Notes
Phenoxybenzamine Overview
- Plasma half-life is approximately 24 hours.
- Not suitable for intravenous administration for all α-blockers, except phentolamine.
- Binds covalently to α-adrenergic receptors, leading to a prolonged effect.
Clinical Uses
- Primarily used to manage symptoms of pheochromocytoma, a tumor causing excess catecholamines.
- Additionally effective in controlling episodes of hypertension and tachycardia due to catecholamine release.
Administration and Dosage
- Active when administered orally, providing a convenient route for patients.
- Duration of action following a single dose can extend beyond 24 hours, due to its irreversible binding mechanism.
Physiological Effects
- Phenoxybenzamine has minimal effect on parasympathetic nerves, focusing its action on sympathetic adrenergic systems.
- Also useful in managing symptoms related to Raynaud's phenomenon and essential hypertension.
Studying That Suits You
Use AI to generate personalized quizzes and flashcards to suit your learning preferences.
Description
Test your knowledge on the pharmacokinetics and mechanisms of action of henoxybenzamine. Learn about its oral and parenteral routes of administration, plasma half-life, duration of action, and its binding to α-1 and α receptors.
